177 related articles for article (PubMed ID: 9361367)
1. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728.
Tsao PW; Forsythe MS; Mousa SA
Thromb Res; 1997 Oct; 88(2):137-46. PubMed ID: 9361367
[TBL] [Abstract][Full Text] [Related]
2. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
Pedicord DL; Thomas BE; Mousa SA; Dicker IB
Thromb Res; 1998 Jun; 90(6):247-58. PubMed ID: 9700855
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-mediated clot retraction by integrin antagonists.
Hantgan RR; Mousa SA
Thromb Res; 1998 Mar; 89(6):271-9. PubMed ID: 9669749
[TBL] [Abstract][Full Text] [Related]
4. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
5. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
6. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
Klinkhardt U; Kirchmaier CM; Westrup D; Breddin HK; Mahnel R; Graff J; Hild M; Harder S
Thromb Res; 2000 Feb; 97(4):201-7. PubMed ID: 10674406
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
8. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.
Naimushin YA; Mazurov AV
Biochemistry (Mosc); 2003 Feb; 68(2):209-16. PubMed ID: 12693968
[TBL] [Abstract][Full Text] [Related]
9. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
12. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
Lages B; Weiss HJ
Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
14. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
Liem TK; Teel R; Shukla S; Silver D
J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.
Ammar T; Scudder LE; Coller BS
Circulation; 1997 Feb; 95(3):614-7. PubMed ID: 9024148
[TBL] [Abstract][Full Text] [Related]
16. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
Coller BS; Lang D; Scudder LE
Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
18. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
Nurden P; Poujol C; Durrieu-Jais C; Winckler J; Combrié R; Macchi L; Bihour C; Wagner C; Jordan R; Nurden AT
Blood; 1999 Mar; 93(5):1622-33. PubMed ID: 10029591
[TBL] [Abstract][Full Text] [Related]
19. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist.
Ogawa T; Sugidachi A; Otsuguro K; Isobe T; Asai F
Biochem Pharmacol; 2002 May; 63(10):1911-8. PubMed ID: 12034376
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
